The U.S. pharmaceutical industry appears to be globally competitive with the industries of Japan and Western Europe, according to a staff research paper recently released by the U.S. International Trade Commission.
Review of Global Competitiveness in the Pharmaceutical Industry reflects research conducted by staff in the agency's Office of Industries. The views and conclusions expressed in the staff research paper do not necessarily reflect the views of the U.S. International Trade Commission or any individual Commissioner.
The staff research paper describes the principal factors currently affecting the competitiveness of the U.S. pharmaceutical industry, particularly in relation to the industries of Western Europe and Japan. It includes overviews of the U.S., Japanese, and Western European industries, with a focus on research and development expenditures, performance in biotechnology, and government policies that directly affect pharmaceutical producers.
Changes affecting the industry worldwide, including widespread tariff eliminations, improved protection for intellectual property rights, and a large number of mergers and acquisitions, are also discussed in the report.
Review of Global Competitiveness in the Pharmaceutical Industry (Staff Research Study 25, USITC Publication 3172, May 1999) is available on the ITC's Internet server at www.usitc.gov. A printed copy may be requested by calling 202-205-1809 or by writing to the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Requests may be faxed to 202-205-2104.